Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from two Phase 3 clinical
trials evaluating ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg
tablets in chronic hepatitis C (HCV) patients with inherited blood
disorders (C-EDGE
IBLD) and in patients with a history of intravenous drug
use who are receiving opioid agonist therapy (C-EDGE
CO-STAR), respectively.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK International Liver Congress MSD ZEPATIER Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Politics | Study | Urology & Nephrology